Vierhapper H, Nowotny P
Division of Clinical Endocrinology and Diabetes Mellitus, I. Medizinische Universitätsklinik, Wien, Austria.
Eur J Clin Invest. 1987 Dec;17(6):544-7. doi: 10.1111/j.1365-2362.1987.tb01155.x.
In healthy, sodium and fluid replete men (n = 6) a transient increase in diuresis is seen during the prolonged infusion of human atrial natriuretic peptide (hANP: 50 micrograms h-1 for 6 h). In order to evaluate whether this evanescent diuretic effect of hANP is due to the peptide's hypotensive action, the latter was compensated for by the concomitant infusion of norepinephrine (NE: 50 ng kg-1 min-1). The decrease in hANP-induced diuresis towards the end of the 6-h infusion was not prevented by the additional infusion of norepinephrine, which also failed to influence hANP-stimulated natriuresis. Plasma concentrations of hANP, which were continuously elevated to about double of basal concentrations during the infusion of hANP, were not affected by exogenous norepinephrine. These data demonstrate that the transient character of hANP-induced diuresis cannot be offset by counterbalancing the peptide's hypotensive effect.
在健康、钠和液体充足的男性（n = 6）中，在长时间输注人心房利钠肽（hANP：50微克/小时，持续6小时）期间，可观察到利尿作用短暂增加。为了评估hANP这种短暂的利尿作用是否归因于该肽的降压作用，通过同时输注去甲肾上腺素（NE：50纳克/千克/分钟）来抵消后者。在6小时输注接近尾声时，hANP诱导的利尿作用降低并未因额外输注去甲肾上腺素而得到阻止，去甲肾上腺素也未能影响hANP刺激的利钠作用。在输注hANP期间，hANP的血浆浓度持续升高至基础浓度的约两倍，但不受外源性去甲肾上腺素的影响。这些数据表明，hANP诱导的利尿作用的短暂特性不能通过抵消该肽的降压作用来抵消。
